Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090542 · ClinicalTrials.gov registry record · NA
GPur- Luminating Oral Cholesterol Kinetics Pilot Study
A NA study of Cholesterol Absorption, sponsored by Canadian Collaborative Research Network.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03090542: Completed NA study of Cholesterol Absorption, sponsored by Canadian Collaborative Research Network.
NCT03090542 is a NA study of Cholesterol Absorption that has completed, run by Canadian Collaborative Research Network. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03090542, a NA study of Cholesterol Absorption, has completed, sponsored by Canadian Collaborative Research Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
In healthy subjects not receiving or requiring lipid lowering therapy and who do not have diabetes, the use of clinoptilolite (GPUR) will result in a reduction of absorbed dietary cholesterol observed over 6 days of therapy.
Primary Outcome
Primary Objective
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT clinoptilolite
Study Locations (1)
Georgia
- Atlanta Heart Specialists - Cumming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2018-01-15 |
| Phase | NA |
What the finished NCT03090542 record still lists
NCT03090542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cholesterol Absorption appearing as the primary indexed condition, and to 1 intervention - of which clinoptilolite is the first listed.
NCT03090542 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03090542 about?
NCT03090542 is a clinical study titled "GPur- Luminating Oral Cholesterol Kinetics Pilot Study". In healthy subjects not receiving or requiring lipid lowering therapy and who do not have diabetes, the use of clinoptilolite (GPUR) will result in a reduction of absorbed dietary cholesterol observed over 6 days of therapy.
What is the current status of trial NCT03090542?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2017-06-01. Estimated completion is 2018-01-15.
What conditions does trial NCT03090542 study?
This clinical trial studies the following conditions: Cholesterol Absorption.
What interventions are being tested in trial NCT03090542?
The interventions under investigation include: clinoptilolite (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03090542?
This trial is sponsored by Canadian Collaborative Research Network, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03090542 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03090542's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI